Newrabell® Tablet 10mg
DrugOther names: Rabeprazole sodium
NCT Number: NCT01860482
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 4
Chonnam National University Hospital, Gwangju, Donggu, Jebongro, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Rabeprazole sodium
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Time frame: up to 8 weeks
Chong Kun Dang Pharmaceutical
Industry
An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04531475
Deglutition Disorders, Digestive System Diseases
Bengbu, Anhui, China
View Trial DetailsNCT05899491
Deglutition Disorders, Digestive System Diseases
Hyderabad, Telangana, India
View Trial DetailsNCT01733810
Deglutition Disorders, Digestive System Diseases
Dallas, Texas, United States
View Trial DetailsNCT01397084
Deglutition Disorders, Digestive System Diseases
View Trial Details